WEST CHESTER, Pa. - Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a company focusing on dermatological therapies, announced today the settlement of its litigation with Dormer Laboratories Inc. The agreement results in Dormer Labs ceasing the sale of all cantharidin-containing products in the United States. This includes their brands Cantharone and Cantharone Plus, which were not approved by the Food and Drug Administration (FDA).
Ted White, President and CEO of Verrica, stated that the settlement underscores the company's commitment to enforcing regulations around drug approval and distribution in the U.S. market. He emphasized the importance of patient safety, highlighting that compounded cantharidin, due to its instability and inconsistent concentration, can be harmful.
The only FDA-approved cantharidin therapy for molluscum contagiosum, a contagious skin disease affecting approximately six million people in the U.S., is Verrica's YCANTH. The product is designed for use by healthcare professionals and is not intended for home application.
YCANTH's approval was based on positive results from two Phase 3 clinical trials involving around 500 patients. It is reported that 228 million lives are covered by insurance for YCANTH treatments, which are available for $25-$75 per treatment. Financial assistance is also mentioned for those in need.
Verrica continues to develop treatments for other skin conditions, including common warts and external genital warts, and has a second cantharidin-based product, VP-103, for plantar warts in the pipeline. Additionally, the company has a worldwide license agreement for VP-315 for the treatment of non-melanoma skin cancers.
The information in this article is based on a press release statement from Verrica Pharmaceuticals Inc.
In other recent news, Verrica Pharmaceuticals has made notable changes to its Credit Agreement and licensing agreement, while also receiving encouraging assessments from analyst firms. The company has amended its existing Credit Agreement, adjusting the revenue test commencement date to September 30, 2024. This amendment affects the requirement for principal payments on the borrowings based on the performance of their product, YCANTH™.
In partnership with Torii Pharmaceutical Co. Ltd., Verrica has also updated their licensing agreement to conduct a global Phase 3 clinical trial for YCANTH®, a treatment for common warts. This development follows Verrica's Q1 2024 report of $3.2 million in net revenues from YCANTH.
Analyst firms Jefferies and H.C. Wainwright have both recently upgraded their price targets for Verrica Pharmaceuticals, citing strong YCANTH prescription growth and sales performance. Jefferies has maintained a Buy rating, anticipating significant revenue growth, while H.C. Wainwright has also maintained a Buy rating, adjusting its expectations for YCANTH sales and Verrica's operating margins for the year 2025 and beyond.
InvestingPro Insights
Following the announcement of Verrica Pharmaceuticals Inc.'s settlement with Dormer Laboratories Inc., investors are keenly observing the financial health and market performance of Verrica (NASDAQ:VRCA). A look at the real-time data from InvestingPro shows a company with a modest market capitalization of $309.24 million, and a strikingly high Price / Book ratio of 205.07 as of the last twelve months ending Q1 2024. This ratio may suggest that the market is pricing the company's book value quite aggressively, reflecting investor expectations for future growth or intellectual property that is not captured on the balance sheet.
One of the key InvestingPro Tips for VRCA is the analysts' anticipation of sales growth in the current year. This aligns with the company's recent developments, including the FDA-approved cantharidin therapy and ongoing projects for various skin conditions. In contrast, the company's gross profit margin stands at -172.86%, indicating that despite revenue growth, profitability remains a challenge, as echoed by another InvestingPro Tip highlighting that analysts do not anticipate the company will be profitable this year.
Investors should note that Verrica is characterized by volatile stock price movements, which could be influenced by market reactions to the settlement news and the company's pipeline developments. Despite the volatility, the company has seen a strong return over the last three months, with a 23.14% price total return, signaling investor confidence in the short term. For those considering a deeper dive into VRCA's financials and future outlook, InvestingPro offers additional tips, with the full suite of insights available at https://www.investing.com/pro/VRCA. Readers can take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, accessing comprehensive analysis and metrics to inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.